Literature DB >> 11305413

Inhibitory effect of epigallocatechin-gallate on brain tumor cell lines in vitro.

S Yokoyama1, H Hirano, N Wakimaru, K P Sarker, J Kuratsu.   

Abstract

We investigated the effect of epigallocatechin-gallate (EGCG), the main constituent of green tea polyphenols, on human glioblastoma cell lines U-373 MG and U-87 MG, rat glioma cell line C6, and rat nonfunctioning pituitary adenoma cell line MtT/E. Cell viability was determined by assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), and the extent of apoptosis was studied by flow cytometric analysis. Apoptosis was also characterized by morphology using fluorescent microscopy. The role of insulin-like growth factor-I (IGF-I) was studied by assay with MTT, immunohistochemistry, and immunoradiometric assay. After 72-h exposure, a statistically significant loss of viability (P = < 0.0001) was observed at concentrations of 12.5, 25, 50, and 100 microg/ml in U-373 MG cells and U-87 MG cells. EGCG at concentrations of 50 microg/ml and higher significantly reduced the viability of C6 cells. EGCG inhibited viability of MtT/E cells only at a concentration of 100 microg/ml. Quantitative study by flow cytometry demonstrated that lower doses of EGCG (12.5, 25, 50 microg/ml) induced apoptosis in U-373 MG, U-87 MG, and C6 cells; however, only the highest dose (100 microg/ml) induced apoptosis in MtT/E cells. Compared with other cell lines, MtT/E cells showed stronger IGF-I immunoreactivity. Neutralization of IGF-I with an antihuman IGF-I antibody reduced viability of the cell lines. It can be concluded that EGCG has an inhibitory effect on malignant brain tumors, and IGF-I may be involved in the effects of EGCG.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11305413      PMCID: PMC1920605          DOI: 10.1093/neuonc/3.1.22

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  10 in total

Review 1.  Phenylpropanoids in radioregulation: double edged sword.

Authors:  Wanyeon Kim; Ki Moon Seong; BuHyun Youn
Journal:  Exp Mol Med       Date:  2011-06-30       Impact factor: 8.718

Review 2.  The chemopreventive and chemotherapeutic potentials of tea polyphenols.

Authors:  Vijay S Thakur; Karishma Gupta; Sanjay Gupta
Journal:  Curr Pharm Biotechnol       Date:  2012-01       Impact factor: 2.837

3.  Combined low dose ionizing radiation and green tea-derived epigallocatechin-3-gallate treatment induces human brain endothelial cells death.

Authors:  Nancy McLaughlin; Borhane Annabi; Marie-Paule Lachambre; Kwang Sik Kim; Jean-Paul Bahary; Robert Moumdjian; Richard Béliveau
Journal:  J Neurooncol       Date:  2006-05-19       Impact factor: 4.130

4.  The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin.

Authors:  Amal Shervington; Vidya Pawar; Sharad Menon; Dipti Thakkar; Rahima Patel
Journal:  Mol Biol Rep       Date:  2008-06-26       Impact factor: 2.316

5.  Molecular docking and molecular dynamics studies reveal structural basis of inhibition and selectivity of inhibitors EGCG and OSU-03012 toward glucose regulated protein-78 (GRP78) overexpressed in glioblastoma.

Authors:  Rituparna Bhattacharjee; Arpita Devi; Seema Mishra
Journal:  J Mol Model       Date:  2015-09-29       Impact factor: 1.810

6.  (-)-Epigallocatechin Gallate Inhibits Asymmetric Dimethylarginine-Induced Injury in Human Brain Microvascular Endothelial Cells.

Authors:  Jia Li; Zhiming Zhang; Lianjie Lv; Haibo Qiao; Xiuju Chen; Changlin Zou
Journal:  Neurochem Res       Date:  2016-04-02       Impact factor: 3.996

7.  Can Tea Consumption be a Safe and Effective Therapy Against Diabetes Mellitus-Induced Neurodegeneration?

Authors:  Ana R Nunes; Marco G Alves; Paula I Moreira; Pedro F Oliveira; Branca M Silva
Journal:  Curr Neuropharmacol       Date:  2014-12       Impact factor: 7.363

8.  Pathway Analysis Revealed Potential Diverse Health Impacts of Flavonoids that Bind Estrogen Receptors.

Authors:  Hao Ye; Hui Wen Ng; Sugunadevi Sakkiah; Weigong Ge; Roger Perkins; Weida Tong; Huixiao Hong
Journal:  Int J Environ Res Public Health       Date:  2016-03-26       Impact factor: 3.390

9.  Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response.

Authors:  Robert Aiken; Magnus Axelson; Johan Harmenberg; Maria Klockare; Olle Larsson; Cecilia Wassberg
Journal:  Oncotarget       Date:  2017-09-06

Review 10.  Natural Compounds as Promising Adjuvant Agents in The Treatment of Gliomas.

Authors:  Francesca Persano; Giuseppe Gigli; Stefano Leporatti
Journal:  Int J Mol Sci       Date:  2022-03-20       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.